Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $2.09bn (+6.0%); adjusted operating margin 29.5%.
Net sales rounded in release; diluted EPS $1.94. Full GAAP figures in annual report.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Aug 2026: QIAGEN named Jon Pratt CEO from 1 Sep 2026, replacing Thierry Bernard, while its supervisory board continued a strategic review with outside advisers. In Mar 2025 QIAGEN began patent litigation to defend its QuantiFERON TB test.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving QIAGEN found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Mar 2025: QIAGEN initiated an FDA Class 2 recall of one lot of QIAstat-Dx Respiratory Panel Plus cartridges (US distribution) after faulty cartridges were found that could give false results; customers were offered free replacements.
Contract delivery, go-lives, terminations and disputes.
Nov 2025: Defra awarded QIAGEN Ltd a £3.1m contract for QIAGEN reagents to March 2028, called off from an NHS Supply Chain framework. No customer disputes or terminations found in HSH's search of the last 24 months.